Navigation Links
Meningococcal-B Vaccine Greatly Reduces The Risk of The Disease

A new study has shown the children and teenagers who had been immunised against epidemic meningococcal B disease are five times less likely to be infected// than those who haven't been vaccinated.

Reports have shown that the biggest mass immunisation campaign that had taken place among the young New Zealanders has resulted in a five-fold reduction in the risk of acquiring Meningococcal B disease. The officials from the Ministry of health have stated that according to the initial results of the study conducted by the Victoria University of Wellington has showed that the children who were not immunised were almost five times more likely to suffer the disease. Stating that this disease has affected nearly 6,000 people since the epidemic began in 1981, they said that this disease has killed 239 people in a 25-year epidemic that has hit the country.

It has been reported that 1-in-5 of the survivors have been left with some degree of disability, that includes hearing loss, brain damage, amputation or scarring. Dr Jane O'Hallahan, the director of the immunisation programme has said that if the current trends continue, then substantial progress will been made towards ending the epidemic by the end of the year, which means it could be ended technically several years before its natural end.

Meningococcal disease is a bacterial infection, which causes severe illnesses including meningitis that is an infection of membranes covering the brain, and septicaemia a serious blood infection. Officials at the ministry have explained hat though anyone is vulnerable to the disease, the biggest risk group would be teenagers and children under 20 yrs of age, and more than half of those in that group are below 5 yrs.


'"/>




Page: 1

Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Vaccine for Alzheimer’s diseas
4. Health Officials Recommend Flu Vaccine
5. Smallpox Vaccine May Help Fight Cervical Cancer
6. Panacea Biotech To Market Anthrax Vaccine
7. New Prostate Cancer Vaccine Shows Promise
8. Drug Firm Offers to Donate Smallpox Vaccine
9. Vaccine guards against shingles
10. Vaccine for septic conditions
11. A new Vaccine for Pneumonia
Post Your Comments:
Breaking Medicine News(10 mins):Health News:REES Announces New Baltimore Office 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 3Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:Obesity and Inactivity -- The Biggest Threat to the Nation's Health 2Health News:Obesity and Inactivity -- The Biggest Threat to the Nation's Health 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 2Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 4Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 5Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 6Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 7Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 8Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 9Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 10Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 11
Breaking Medicine Technology:Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 2HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 3Sam 26apos 3Bs Club Tailgate Challenge Video Contest 3A Show Sam 26apos 3Bs Club Your Best Tailgating Style for a Chance To Win a 241 000 Gift Card 58561 1Sam 26apos 3Bs Club Tailgate Challenge Video Contest 3A Show Sam 26apos 3Bs Club Your Best Tailgating Style for a Chance To Win a 241 000 Gift Card 58561 2Sam 26apos 3Bs Club Tailgate Challenge Video Contest 3A Show Sam 26apos 3Bs Club Your Best Tailgating Style for a Chance To Win a 241 000 Gift Card 58561 3Cephalon Third Quarter 2009 Earnings Conference Call to be held Tuesday October 27 2009 at 5 3A00 p m EDT 58556 1DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX 14301 1DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX 14301 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX 14301 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX 14301 4